Headlands Research (www.headlandsresearch.com), a global next-generation clinical research site organization, today announced that it has acquired Artemis Institute for Clinical Research. The acquisition significantly strengthens Headlands’ ability to profoundly impact the clinical trials process and elevates its global footprint to 13 clinical trial sites.
“Artemis brings a highly experienced and talented research team who cover a wide range of therapeutic areas that align with several of our Centers of Excellence, including Psychiatry, Neurology, and Vaccine trials,” said Mark Blumling, CEO and Founder of Headlands Research. “We believe Artemis’ expertise complements Headlands’ global portfolio of clinical trial research competencies, and of equal importance, further builds upon our significant commitment to diversity in clinical trial enrollment.”
Artemis Institute for Clinical Research was founded by Dr. Vishaal Mehra in 2008 with the purpose of prioritizing patients and advancing medicine. With locations in San Diego and Riverside, Artemis specializes in the areas of Psychiatry, Neurology, Vaccine, Inpatient, and Medical Device clinical trials. To date, Artemis has conducted over 500 clinical trials across 20 therapeutic areas.
“We are very excited to be joining Headlands Research and we share in their vision to dramatically improve the clinical trial process,” said Dr. Vishaal Mehra, CEO and founder of Artemis Institute for Clinicals Research. “We are impressed with the leadership, innovation and growth trajectory of Headlands Research and believe that together we can continue to expand our research efforts in Southern California.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.